SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Michael Saylor Says Bitcoin's Next Bull Run Has Begun, Sees It Back In 'Six Figures' Within A Year

Equity

Saylor expects Bitcoin to top $100,000 within a year, but added that, "I can't be sure it happens by the end of the year."

Bitcoin-Backed Stablecoin? Michael Saylor Says Digital Dollars Could Offer 7% Yield 

Saylor outlined a vision for yield-bearing digital dollars built on Bitcoin-backed credit instruments, with Strategy’s STRC playing a role in the proposed financial model. 

Michael Saylor Calls CLARITY Act Rejection A ‘Positive Inflection Point’ For Crypto Industry

Michael Saylor argued mass adoption was the industry's real protection against a hostile administration.


Strategy CEO Says Banks Pushed Firm To Selling Bitcoin: ‘Never Sell’ Was Never A Rule

Strategy CEO Phong Le said that banks pushed the company to show it was willing to sell Bitcoin before treating the asset as usable collateral.

Strategy's Phong Le Defends Buying Bitcoin At $80K After Selling Near $60K: ‘Right Trade’

Phong Le said in an interview with Bloomberg that Strategy's balance sheet grew to $72 billion in assets over two months.

Michael Saylor’s Strategy Calls MSCI’s New Delisting Test ‘Fundamentally Flawed,’ Says It’s Damaging ‘Its Reputation’

Strategy asked MSCI to withdraw the proposal or apply changes only prospectively going forward.

Michael Saylor Hints At Strategy’s Return To Bitcoin Buying After 10-Week Hiatus

Strategy Inc has not disclosed a Bitcoin purchase since acquiring 520 BTC for the week of June 15 to June 21.

Peter Schiff Says Strategy's Common Stock Will Eventually Be Worthless As Michael Saylor Says STRC Is The Biggest Position In Three Major ETFs

Schiff also reiterated his bearish Bitcoin outlook, warning a break below $50,000 could trigger a deeper decline toward the $20,000-$30,000 range.

MSTR’s Michael Saylor Rips BIP-110 As 'Alien' To Bitcoin's Soul, Calls It Monetary Purity By Fiat

Bitcoin community figures such as Adam Back, Greg Maxwell, and Peter Todd have voiced concerns about the design and activation process of BIP-110.

Michael Saylor's Bitcoin Credibility Splits Two Market Veterans Over ‘Buying Forever’ Pledge

Irons highlighted Saylor’s earlier pledge to keep buying Bitcoin indefinitely and questioned the firm's reduced emphasis on its "Bitcoin yield" metric.


Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Michael Saylor said Bitcoin is at "the beginning of the next bull run" after it bounced off the 200-week moving average.</li><li>Saylor called the CLARITY Act "a bill of restrictions," and said regulators issued guidance that "provided rights to the industry" after it stalled.</li><li>Clear Street raised its Strategy price target to $211 from $201 ahead of the Oct. 29 earnings, still below the $239.27 Street average on Koyfin.</li></ul>Strategy (MSTR) executive chairman Michael Saylor said Bitcoin (BTC) was at "the beginning of the next bull run," adding that he expects the cryptocurrency to break above $100,000 "sometime in the next 12 months."Saylor&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=BhltoFxmVs8">said</a> on the Market Overtime show on the Charles Schwab Network that Bitcoin "bounced off the 200-week moving average," a level he described as the usual floor for a bear market. It has since rallied about $20,000 from there, he said.&nbsp;He stopped short of naming a year-end target. "I can't be sure it happens by the end of the year, but I feel like we're definitely moving back into the six figures at this point," Saylor said. Asked how long a bull market lasts, he answered, "Four years."<a href="https://stocktwits.com/symbol/MSTR">MSTR stock</a> was up over 5% during midday trade on Tuesday. On Stocktwits, the retail sentiment around MSTR remained in the ‘bearish’ zone, while chatter levels around it stayed at ‘normal’ levels over the past day.<h2 class="st-heading-2">Tailwinds Building</h2>Saylor said Bitcoin had been held back by restrictive foreign, monetary, and trade policy, as well as an AI boom that drew capital away from crypto. He said those pressures are now being priced in.In their place, he pointed to digital credit, banks lending against Bitcoin, and supportive guidance from the Treasury, the Commodity Futures Trading Commission (CFTC), and the U.S. Securities and Exchange Commission (SEC).Monetary policy remained the biggest swing factor, he said. "The final boss that generally drives all assets is monetary policy," Saylor said, adding that "Bitcoin tends to react like risk squared right now."<h2 class="st-heading-2">'A Bill Of Restrictions'</h2>Saylor also explained why he saw the stalled Digital Asset Clarity Act (CLARITY Act) as good news for the industry.&nbsp;He called the legislation "a bill of restrictions," when what the industry needed was "a bill of rights." After the bill stalled, Saylor said regulators issued "a whole set of guidance rules that provided rights to the industry." Those included rules on tokenization, digital derivatives, prediction markets and digital currency.<h2 class="st-heading-2">Clear Street Raises Strategy Price Target Ahead Of Earnings</h2>Strategy also drew a vote of confidence from Wall Street ahead of its third-quarter (Q3) results scheduled for October 29. Clear Street raised its price target on the stock to $211 from $201 and kept a ‘Buy’ rating, according to TheFly.&nbsp;The firm said Strategy strengthened its funding position in the quarter. It sold common stock to&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/michael-saylor-strategy-boosts-strc-buyback-program-to-3-b-keeps-btc-buying-muted/cZx8oG5RBMY">buy back preferred shares and build its dollar reserves</a>. With its preferred stock now trading close to par, Clear Street said Strategy was better placed to resume preferred sales and grow its Bitcoin per share again.Clear Street's new target still sits below the Street average of $239.27, according to Koyfin data. Of the 16 analysts covering the stock, 15 rate it a ‘Buy’ or ‘Strong Buy’.&nbsp;Strategy is known for being a digital asset treasury (DAT) with around 848,517 BTC in its holdings. Bitcoin was one of the top-trending tickers on Stocktwits at the time of writing.&nbsp;<a href="https://stocktwits.com/coins/bitcoin">Bitcoin’s price</a> was trading at around $82,400, up over 0.6% over the past 24 hours. That price values Strategy’s Bitcoin holdings at around $69.92 billion.On Stocktwits, the retail sentiment around BTC moved to the ‘bearish’ zone from the ‘extremely bearish’ zone, while chatter around it stayed at ‘low’ levels over the past day.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-exposure-with-less-downside-risk-blackrock-new-etf/cZxqUdsRBux">BlackRock Files Its Third Bitcoin ETF, A 'Buffer' Fund That Targets Investors Seeking Downside Protection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Michael J. Saylor attends Consensus Miami 2026 at Miami Beach Convention Center on May 06, 2026 in Miami Beach, Florida. (Photo by Romain Maurice/Getty Images)

Strategy (MSTR) executive chairman Michael Saylor said Bitcoin (BTC) was at "the beginning of the next bull run," adding that he expects the cryptocurrency to break above $100,000 "sometime in the next 12 months."

T-Rex 2X Long MSTR Daily Target ETF

YieldMax MSTR Option Income Strategy ETF

T-Rex 2X Inverse MSTR Daily Target ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$MSTY 
Adding a few more this morning trying to get to 5k before the Bull really starts to run. GLTA

Chris

$MSTY beautiful MSTY divvy !   Can you imagine what it’s going to look like when Bitcoin rockets to 150 k ? $BTC.X

Lieutenant Joe

$MSTY Fear ,fear  fears 

What do we do when there is so many fears?

To each it's own. 

Do what's best for you .

The markets will always be here.

Yogie 26

$MSTY 

The amount of dead bodies stacked on top of this price level is ridiculous. 

Divy is nice, but price won't move higher for a long time.

Nadyr A

$MSTY I’ll re enter when there’s a confirmed uptrend. Remember, these aren’t investments. Don’t get caught up in the dividend.

Andrew

$MSTY It should be illegal to short this turd!  Talk about a consistent cash cow.  Can't wait for the next reverse split before the end of the year!!

Jon Gaudino

$MSTY I bought 983 shares October 7th at 9:21 p.m. thanks to the 24-hour trading. I just saw I am not getting credit to get the dividend today. The ex-dividend date is October 8th. Robinhood is showing that my shares didn't settle until October 9th, today. With my shares showing a settled date of October 9th, am I fucked out of the dividend?

Feed

News

Sentiment

Fundamentals

Info

MSTY YieldMax MSTR Option Income Strategy ETF

Fundamentals

Latest MSTY News